#National Institutes of Health

A carbohydrate called heparan sulfate, found on cell surfaces, may help the new coronavirus infects cells.

The study asks whether certain approved therapies or late-stage investigational drugs show promise against COVID-19.

It’s part of a $234 million federal initiative to improve COVID-19 testing among vulnerable populations.

New findings may explain why some people with COVID-19 develop more severe disease.

The trial is evaluating an investigational vaccine from Janssen that may require only one shot.

Researchers hope to combine gene editing with a less toxic stem cell transplant. Findings may apply to cancer and other illnesses.

Based on antibodies isolated from llamas, researchers engineered an antibody that prevented SARS-CoV-2 from entering cells.

As a result, researchers in Spain are testing whether HIV med Truvada, often used as PrEP, can also prevent COVID-19.

The trial will enroll healthy volunteers to test the vaccine’s safety and ability to trigger an immune response.

SARS-CoV-2 stability similar to original SARS virus.

But it comes with deep cuts to Medicare, Medicaid, Social Security, cancer funds and other health and science programs.

The National Cancer Institute stands to lose more than $500 million, and cancer prevention programs are at risk.

The American Cancer Society sets the record straight.

Using such products increased their risk by 60% and 30%, respectively.

Last year, the federal agency invested nearly $300 million in the search for HIV cure therapies.

The study of a contraceptive gel for men is ongoing.